Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 0.47%.

  • Altimmune's Return on Capital Employed rose 2600.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year increase of 2600.0%. This contributed to the annual value of 0.63% for FY2024, which is 1400.0% down from last year.
  • Altimmune's Return on Capital Employed amounted to 0.47% in Q3 2025, which was up 2600.0% from 0.57% recorded in Q2 2025.
  • In the past 5 years, Altimmune's Return on Capital Employed ranged from a high of 0.25% in Q1 2021 and a low of 0.78% during Q4 2024
  • Its 5-year average for Return on Capital Employed is 0.52%, with a median of 0.5% in 2023.
  • In the last 5 years, Altimmune's Return on Capital Employed soared by 3000bps in 2021 and then tumbled by -2700bps in 2022.
  • Over the past 5 years, Altimmune's Return on Capital Employed (Quarter) stood at 0.46% in 2021, then grew by 5bps to 0.44% in 2022, then fell by -23bps to 0.54% in 2023, then plummeted by -43bps to 0.78% in 2024, then skyrocketed by 39bps to 0.47% in 2025.
  • Its last three reported values are 0.47% in Q3 2025, 0.57% for Q2 2025, and 0.71% during Q1 2025.